Acasti Pharma Inc

(NASDAQ:ACST)

Latest On Acasti Pharma Inc (ACST):

Date/Time Type Description Signal Details
2023-04-04 09:45 ESTNewsAcasti Pharma announces CEO transitionN/A
2023-02-14 18:47 ESTNewsAcasti Pharma GAAP EPS of -C$0.09N/A
2023-02-14 18:46 ESTNewsAcasti Pharma Inc. (ACST) Q3 2023 Earnings Call TranscriptN/A
2023-01-25 13:16 ESTNewsAcasti receives extension to regain compliance with minimum bid requirementN/A
2022-12-28 23:46 ESTNewsAcasti soars ~15% as phase 1 bridging study of neurodegenerative disorder drug shows promiseN/A
2022-11-15 14:33 ESTNewsAcasti Pharma Inc. (ACST) Q2 2023 Earnings Call TranscriptN/A
2022-11-14 21:47 ESTNewsAcasti Pharma GAAP EPS of -$0.11N/A
2022-09-30 13:01 ESTNewsAcasti says court dismissed challenge to Grace Therapeutics acquisitionN/A
2022-09-14 00:16 ESTNewsAcasti begins dosing of GTX-102 for neurodegenerative disorder; appoints chief commercial officerN/A
2022-08-11 22:17 ESTNewsAcasti Pharma GAAP EPS of -$0.10N/A
2022-08-11 22:16 ESTNewsAcasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q1 2023 Results - Earnings Call TranscriptN/A
2022-06-21 22:02 ESTNewsAcasti Pharma reports GAAP EPS of $0.27 for FY2022N/A
2022-06-21 22:01 ESTNewsAcasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2022 Results - Earnings Call TranscriptN/A
2022-06-14 11:46 ESTNewsAcasti gets patents related to brain hemorrhage drug GTX-104, pain therapy GTX-101N/A
2022-05-18 20:46 ESTNewsAcasti says pharmacokinetic trial for lead asset met all study goalsN/A
2022-02-15 17:47 ESTNewsAcasti Pharma Inc.'s (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call TranscriptN/A
2022-02-14 23:17 ESTNewsAcasti Pharma GAAP EPS of -$0.09 misses by $0.01N/A
2022-02-14 23:16 ESTNewsAcasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call TranscriptN/A
2022-01-11 07:31 ESTNewsAcasti Pharma (ACST) Investor Presentation - SlideshowN/A
2021-12-22 11:31 ESTNewsAcasti Pharma jumps 21% on new Outperform rating at Oppenheimer with PT of $6N/A
2021-12-02 12:16 ESTNewsAcasti says candidate for subarachnoid hemorrhage met main goals in pivotal PK studyN/A
2021-11-11 00:18 ESTNewsAcasti Pharma EPS beats by $0.60N/A
2021-11-11 00:16 ESTNewsAcasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earning Call TranscriptN/A
2021-11-10 01:32 ESTNewsAcasti Pharma Q2 Earnings PreviewN/A
2021-09-27 11:49 ESTNewsAcasti Pharma initiates pharmacokinetic bridging study for lead candidate GTX-104N/A
2021-09-22 20:03 ESTNewsAcasti Pharma regains compliance with Nasdaq's listing ruleN/A
2021-09-04 05:45 ESTNewsInnate Pharma, Adagio top weekly healthcare gainers, Acasti Pharma, Forte Biosciences trailN/A
2021-08-27 23:17 ESTNewsAcasti Pharma to effect 8-1 reverse stock split, closes Grace Therapeutics mergerN/A
2021-08-12 11:32 ESTNewsAcasti Pharma reports FQ1 resultsN/A
2021-07-20 17:44 ESTNewsAcasti updates on acquisition of Grace Therapeutics and announces fiscal 2021 resultsN/A
2021-05-07 23:03 ESTNewsAcasti inks deal for Grace Therapeutics, shares surgeN/A
2021-02-11 07:01 ESTFinancialsCompany financials have been released.Neutral
2021-02-09 08:01 ESTNewsAcasti Pharma EPS beats by $0.01N/A
2020-12-24 01:32 ESTNewsWATT, MVIS, SOL and ONTX among midday moversN/A
2020-12-24 01:31 ESTNewsAcasti Pharma issues clarification on trading activityN/A
2020-11-25 11:03 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 11:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-16 08:01 ESTNewsAcasti Pharma EPS in-lineN/A
2020-11-01 16:50 ESTFinancialsCompany financials have been released.Neutral
2020-09-29 21:03 ESTNewsAcasti announces initiation of strategic alternative processN/A
2020-09-26 04:02 ESTFinancialsCompany financials have been released.Neutral
2020-09-24 16:02 ESTFinancialsCompany financials have been released.Neutral
2020-09-22 21:08 ESTNewsBank-backed stock exchange launches to rival Nasdaq, NYSEN/A
2020-09-16 11:18 ESTNewsNew finance chief at Acasti PharmaN/A
2020-09-01 01:04 ESTNewsAcasti Pharma's CaPre flunks late-stage study, shares down 60%N/A
2020-08-16 04:01 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 10:01 ESTNewsAcasti Pharma reports Q1 resultsN/A
2020-08-06 20:01 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:04 ESTFinancialsCompany financials have been released.Neutral
2020-07-03 04:01 ESTFinancialsCompany financials have been released.Neutral

About Acasti Pharma Inc (ACST):

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST Quotes by TradingView

See Advanced Chart

General

  • Name Acasti Pharma Inc
  • Symbol ACST
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 32
  • Last Split Factor1:10
  • Last Split Date2015-10-15
  • Fiscal Year EndMarch
  • IPO Date2011-05-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.acastipharma.com
View More

Valuation

  • Trailing PE 25.48
  • Price/Sales (Trailing 12 Mt.) 840.21
  • Price/Book (Most Recent Quarter) 5.63
  • Enterprise Value Revenue 1430.78
  • Enterprise Value EBITDA 27.83
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin 3189%
  • Operating Margin -16852%
  • Return on Assets -28%
  • Return on Equity 25%
  • Revenue 81000
  • Earnings Per Share $0.03
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 138.28 million
  • Analyst Target Price $2.52
  • Book Value Per Share $0.17
View More

Share Statistics

  • Shares Outstanding 200.12 million
  • Shares Float 179.14 million
  • % Held by Insiders 864%
  • % Held by Institutions 1.66%
  • Shares Short 1.33 million
  • Shares Short Prior Month 1.78 million
  • Short Ratio 0.03
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.52
  • 52 Week High $1.22
  • 52 Week Low $0.18
  • 50 Day Moving Average 0.79
  • 200 Day Moving Average 0.42
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Acasti Pharma Inc (ACST) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Acasti Pharma Inc (ACST) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-09$N/A-$0.03-$0.0426.41%
2020-09-302020-11-16$N/A-$0.06-$0.05-20.52%
2020-06-302020-08-13$N/A-$0.05-$0.0617.05%
2020-03-312020-06-29$N/A-$0.06-$0.0831.27%
2019-12-312020-02-14$N/A-$0.14-$0.07-88.09%
2019-09-302019-11-13$N/A-$0.26-$0.08-208.78%
2019-06-302019-08-14$N/A-$0.11-$0.1311.68%
2019-03-312019-06-26$N/A-$0.15-$0.12-29.02%
2018-12-312019-02-14$N/A-$0.05-$0.0830.11%
2018-09-302018-11-14$N/A-$0.47-$0.11-343.05%
2018-06-302018-08-14$N/A-$0.18-$0.2013.56%
2018-03-312018-06-27$N/A-$0.24-$0.23-2.84%
2017-12-312018-02-14$N/A-$0.32-$0.23-40.93%
2017-09-302017-11-13$N/A-$0.24-$0.24-1.46%
2017-06-302017-08-14$N/A-$0.14
2016-12-312017-01-12$N/A-$0.17
2016-09-302016-10-11$N/A-$0.17
2016-06-302016-07-11$N/A-$0.23
2016-03-312016-05-25$N/A-$0.13
2015-12-312016-01-12$15509.6-$0.16
2015-09-302015-10-14$3741.67-$0.09
2015-06-302015-07-13$5328.46-$0.07
2015-03-312015-05-27$3992.65-$0.18
2014-12-312015-01-13$142788.77$0.30-$0.30200%
2014-09-302014-10-14$24713.15-$0.30-$0.300%
2014-06-302014-07-15$7358.35$0.10-$0.30133.33%
2014-03-312014-05-21$51376.15-$0.20-$0.3033.33%
2013-12-312014-01-14$180733.78-$0.44
2013-09-302013-10-30$27242.84-$0.41
2013-06-302013-07-31$252252.25-$0.26
2013-03-312013-05-28$5781.46-$0.27
2012-09-302012-11-30$426387.77-$0.22
2012-06-302012-08-31$240243.28-$0.24
2012-03-312012-05-31$13547.51-$0.22
2011-12-312012-02-29$10105.09-$0.23
2011-09-302011-11-30$-32371.98-$0.31
2011-06-302011-08-31$33742.33-$0.27
2011-03-312011-05-31$85699.54-$0.17

Acasti Pharma Inc (ACST) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A N/A 3.9 million
Income Before Tax N/A N/A N/A N/A -12.11 million
Selling General Administrative N/A N/A N/A N/A 2.15 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A N/A -6.05 million
Operating Income N/A N/A N/A N/A -6.05 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A -6.06 million
Net Income From Continuing Operations N/A N/A N/A N/A -12.11 million
Net Income Applicable to Common Shares -3.22 million -6.15 million -4.67 million 13.87 million -12.11 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A 3.37 million
Change to Liabilities -2.35 million N/A 2.18 million N/A -1.86 million
Total Cash Flow from Investing Activities -33000 -36000 -219317 -206344.32 3.46 million
Net Borrowings N/A N/A -1.56 million N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A 7.28 million 6.55 million
Change to Operating Activities 274000 -1.2 million -2.6 million -2.06 million 146514.61
Change in Cash N/A N/A N/A -103172.16 3.69 million
Total Cash from Operating Activities -4.18 million -4.31 million -4.12 million -7.08 million -6.25 million
Depreciation N/A N/A N/A 558977.52 509780.23
Other Cash Flow from Investing Activities N/A N/A -257506 47736.37 104221.74
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A 453137.98
Other Cash Flow from Financing Activities -1000 N/A 78310 -23098.24 -30209.2
Change to Net Income 3.64 million 1.01 million -18.39 million 6.53 million 15.9 million
Capital Expenditures N/A N/A N/A 254080.69 13594.14
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A N/A 34.69 million
Total Stockholder Equity N/A N/A N/A N/A -4.76 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A N/A N/A 29.93 million
Common Stock 162.2 million 142.57 million 139.19 million 137.42 million 125.67 million
Other Current Assets 1.09 million 1.05 million N/A N/A 340314.14
Retained Earnings -140.37 million -137.15 million -131.01 million -126.34 million -138.41 million
Other Liabilities 2.34 million 1.17 million 3.07 million 2.39 million 23.68 million
Other Assets N/A N/A 192000 473000 328765.01
Cash N/A N/A N/A N/A 19.77 million
Total Current Liabilities 2.25 million 3.75 million N/A N/A 11.01 million
Other Stockholder Equity -6.93 million -7.4 million -7.58 million -7.89 million 204034.49
Property, Plant & Equipment 105000 119000 2.06 million 2.06 million 2.19 million
Total Current Assets 30.2 million 13.71 million N/A N/A 22.8 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 25.72 million 8.87 million 7.11 million 8.75 million -9.38 million
Short Term Investments N/A N/A N/A N/A 20018.48
Long Term Debt N/A N/A N/A N/A N/A
Inventory 14000 N/A N/A N/A N/A
Accounts Payable 2.14 million 3.67 million N/A N/A 9.5 million

Acasti Pharma Inc (ACST) Chart:

Acasti Pharma Inc (ACST) News:

Below you will find a list of latest news for Acasti Pharma Inc (ACST) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Acasti Pharma Inc (ACST) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ACST Trades:

Date Shares Price
Jun 13, 2022 7:47 PM EST14$0.9635

Acasti Pharma Inc (ACST) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320004630/0001171843-20-004630-index.htm
2018-10-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1444192/000000000018030970/0000000000-18-030970-index.htm
2019-08-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1444192/000000000019012252/0000000000-19-012252-index.htm
2020-07-02UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1444192/000000000020005967/0000000000-20-005967-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1444192/000110465920019886/0001104659-20-019886-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1444192/000114420419007131/0001144204-19-007131-index.htm
2018-06-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318004470/0001171843-18-004470-index.htm
2018-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318004540/0001171843-18-004540-index.htm
2018-06-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318004590/0001171843-18-004590-index.htm
2018-06-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318004855/0001171843-18-004855-index.htm
2018-06-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318004859/0001171843-18-004859-index.htm
2018-06-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/0001171843-18-004911-index.htm
2018-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318004979/0001171843-18-004979-index.htm
2018-07-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318005301/0001171843-18-005301-index.htm
2018-07-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318005572/0001171843-18-005572-index.htm
2018-08-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318005581/0001171843-18-005581-index.htm
2018-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006051/0001171843-18-006051-index.htm
2018-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006069/0001171843-18-006069-index.htm
2018-08-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006312/0001171843-18-006312-index.htm
2018-09-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006587/0001171843-18-006587-index.htm
2018-09-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1444192/000117184318006662/0001171843-18-006662-index.htm
2018-09-21POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1444192/000117184318006663/0001171843-18-006663-index.htm
2018-09-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006674/0001171843-18-006674-index.htm
2018-10-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006792/0001171843-18-006792-index.htm
2018-10-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006838/0001171843-18-006838-index.htm
2018-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006843/0001171843-18-006843-index.htm
2018-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006844/0001171843-18-006844-index.htm
2018-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006871/0001171843-18-006871-index.htm
2018-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006872/0001171843-18-006872-index.htm
2018-10-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006899/0001171843-18-006899-index.htm
2018-10-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006923/0001171843-18-006923-index.htm
2018-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006946/0001171843-18-006946-index.htm
2018-10-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1444192/000117184318006964/0001171843-18-006964-index.htm
2018-10-12POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1444192/000117184318006965/0001171843-18-006965-index.htm
2018-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318006986/0001171843-18-006986-index.htm
2018-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318007116/0001171843-18-007116-index.htm
2018-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318007675/0001171843-18-007675-index.htm
2018-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318007933/0001171843-18-007933-index.htm
2018-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318007938/0001171843-18-007938-index.htm
2018-12-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318008511/0001171843-18-008511-index.htm
2018-12-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184318008592/0001171843-18-008592-index.htm
2019-01-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319000201/0001171843-19-000201-index.htm
2019-02-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319000816/0001171843-19-000816-index.htm
2019-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319000909/0001171843-19-000909-index.htm
2019-02-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1444192/000117184319000911/0001171843-19-000911-index.htm
2019-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319000912/0001171843-19-000912-index.htm
2019-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319000913/0001171843-19-000913-index.htm
2019-02-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319001076/0001171843-19-001076-index.htm
2019-03-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319001690/0001171843-19-001690-index.htm
2019-03-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319001975/0001171843-19-001975-index.htm
2019-04-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319002400/0001171843-19-002400-index.htm
2019-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319002575/0001171843-19-002575-index.htm
2019-05-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319003237/0001171843-19-003237-index.htm
2019-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319003365/0001171843-19-003365-index.htm
2019-05-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319003528/0001171843-19-003528-index.htm
2019-06-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319003802/0001171843-19-003802-index.htm
2019-06-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319004048/0001171843-19-004048-index.htm
2019-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319004136/0001171843-19-004136-index.htm
2019-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319004173/0001171843-19-004173-index.htm
2019-06-2620-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1444192/000117184319004174/0001171843-19-004174-index.htm
2019-07-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319004427/0001171843-19-004427-index.htm
2019-07-15POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1444192/000117184319004590/0001171843-19-004590-index.htm
2019-07-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319004877/0001171843-19-004877-index.htm
2019-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319005174/0001171843-19-005174-index.htm
2019-08-07F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1444192/000117184319005217/0001171843-19-005217-index.htm
2019-08-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319005223/0001171843-19-005223-index.htm
2019-08-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1444192/000117184319005356/0001171843-19-005356-index.htm
2019-08-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319005364/0001171843-19-005364-index.htm
2019-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319005482/0001171843-19-005482-index.htm
2019-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319005484/0001171843-19-005484-index.htm
2019-08-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319005699/0001171843-19-005699-index.htm
2019-09-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319005786/0001171843-19-005786-index.htm
2019-09-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319005862/0001171843-19-005862-index.htm
2019-09-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319006188/0001171843-19-006188-index.htm
2019-10-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319006227/0001171843-19-006227-index.htm
2019-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319007107/0001171843-19-007107-index.htm
2019-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319007218/0001171843-19-007218-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319007299/0001171843-19-007299-index.htm
2019-11-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319007484/0001171843-19-007484-index.htm
2019-11-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319007485/0001171843-19-007485-index.htm
2019-11-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319007619/0001171843-19-007619-index.htm
2019-11-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319007828/0001171843-19-007828-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184319008308/0001171843-19-008308-index.htm
2020-01-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184320000177/0001171843-20-000177-index.htm
2020-02-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184320000806/0001171843-20-000806-index.htm
2020-02-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184320000950/0001171843-20-000950-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184320000981/0001171843-20-000981-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184320000982/0001171843-20-000982-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184320001384/0001171843-20-001384-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1444192/000117184320001625/0001171843-20-001625-index.htm
2020-04-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002257/0001171843-20-002257-index.htm
2020-04-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002258/0001171843-20-002258-index.htm
2020-04-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002259/0001171843-20-002259-index.htm
2020-04-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002260/0001171843-20-002260-index.htm
2020-04-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002261/0001171843-20-002261-index.htm
2020-04-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002262/0001171843-20-002262-index.htm
2020-04-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002263/0001171843-20-002263-index.htm
2020-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002270/0001171843-20-002270-index.htm
2020-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320002717/0001171843-20-002717-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320003135/0001171843-20-003135-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320004446/0001171843-20-004446-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320004607/0001171843-20-004607-index.htm
2020-06-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1444192/000117184320004613/0001171843-20-004613-index.htm
2020-06-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1444192/000117184320004618/0001171843-20-004618-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320004630/0001171843-20-004630-index.htm
2020-07-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1444192/000117184320004745/0001171843-20-004745-index.htm
2020-07-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1444192/000117184320004805/0001171843-20-004805-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320005439/0001171843-20-005439-index.htm
2020-08-10PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320005755/0001171843-20-005755-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320005899/0001171843-20-005899-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1444192/000117184320005901/0001171843-20-005901-index.htm
2020-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006188/0001171843-20-006188-index.htm
2020-09-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006363/0001171843-20-006363-index.htm
2020-09-11DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006408/0001171843-20-006408-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006409/0001171843-20-006409-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006507/0001171843-20-006507-index.htm
2020-09-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006608/0001171843-20-006608-index.htm
2020-09-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006713/0001171843-20-006713-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006824/0001171843-20-006824-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1444192/000117184320006922/0001171843-20-006922-index.htm
2019-08-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1444192/000119312519209274/0001193125-19-209274-index.htm
2019-07-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1444192/000143774919014281/0001437749-19-014281-index.htm
2018-10-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1444192/999999999518002640/9999999995-18-002640-index.htm
2019-07-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1444192/999999999519001622/9999999995-19-001622-index.htm
2019-08-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1444192/999999999519001853/9999999995-19-001853-index.htm
2020-07-07EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1444192/999999999520001706/9999999995-20-001706-index.htm